About Shockwave Medical

Now a part of Johnson & Johnson MedTech

Same Shock, Bigger Waves

At Shockwave, innovation is in our DNA. We never settle for the status quo and are constantly pioneering ways to address unmet clinical needs with low-risk treatment options for underserved patient populations suffering from cardiovascular disease. From Intravascular Lithotripsy (IVL) to Coronary Sinus Reduction and beyond, our technologies transform lives around the world.

As part of Johnson & Johnson MedTech, we’ll continue to deliver our same unmatched commitment to innovation, customer service and improving patient outcomes. In fact, the added strength of the global leader in healthcare energizes our ability to make even bigger waves – and the future looks shockingly bright.

  • Focus on innovation

    We take a proactive approach to innovation, including identifying opportunities to improve our core products. Most importantly, we’re always coming up with ideas that can become the next breakthrough technology.

  • Focus on the patient

    Our commitment to innovation translates into a commitment to better patient care, ensuring that everything we do ultimately serves patients and promotes better outcomes.

  • Focus on the physician

    As we continue to innovate, we make sure to collaborate with physician partners along the way, getting real-world feedback on current and future technologies to meet and exceed both physician and patient needs.

  • Focus on our people

    Innovation doesn’t just live within R&D — it lives throughout our entire organization. We foster a diversity of experiences and expertise to create a motivated and creative team of people who are passionate about making a difference in patients’ lives.

A Proven Crack Record

Statistics Callout

This section presents key statistical information with numbers and descriptions.

  • 10
    Products launched since 2017
  • 281
    Global patents
  • 38
    R&D projects in progress means innovation never stops
  • 70
    Countries served, helping patients across the globe
  • 1
    million+
    IVL patients treated to date
  • 20,000
    +
    Patient outcomes published
  • 500
    +
    Journal articles published validating the safety & efficacy of IVL
  • 0
    Backorders to date
Our Journey from Pioneering IVL to 1 Million Patients Treated

Generating Innovation. Transforming Patient Care.

Follow our journey from pioneering IVL to treating our one millionth patient and see how our consistent safety and efficacy energized our growth – and our impact.

Our Transformative Technologies

Awards

  • ISS ESG 2024 Prime status

    For our ongoing commitment to responsible governance, environmental and social practices.
    Read More

  • Newsweek 2024 America’s Greenest Companies

    For our innovative, problem-solving approach to reducing environmental impact and stepping up as a sustainability leader in our industry.
    Read More

  • Fast Company 2023 Best Workplaces for Innovators

    For our 2nd straight year, this time as a Best Workplace for Women Innovators due to a diverse female workforce and broader emphasis on improving representation in our industry.
    Read More

  • Edison Awards 2023 Gold

    For our Novel Medical application, coronary Intravascular Lithotripsy, chosen by some of the world’s top senior business executives, designers, academics and innovation leaders.
    Read More

  • Phoenix: The Medical Device and Diagnostic Conference for CEOs 2022 Emerging Growth Company Award

    For outstanding achievement in the medical device and diagnostic industry, selected by CEOs of Phoenix sponsor companies and attendees.
    Read More

  • 2022 Supplier Horizon Award

    For our unwavering commitment to delivering top value products and services designed to continually improve patient care.
    View More

  • 2022 Most Innovative Companies: Medical Device

    For making the biggest impact in our industry with innovation that permeates every aspect of our business.
    Read More
Chalk, Organic Eggs & Cadaver Legs: IVL's Journey from Idea to Reality

Chalk, Organic Eggs & Cadaver Legs

In 2009, a marketer, engineer and cardiologist came together to change the nature of interventional therapy for calcified cardiovascular disease. They envisioned a future in which lithotripsy, a trusted technology used to break kidney stones, could be adapted to crack calcified lesions in a safe and easy manner. What started out as a crazy idea has changed the standard of care for patients with cardiovascular disease around the globe.   

  • Shockwave Leadership

    Commitment beyond compare, with leaders dedicated to their teams. Meet the Shockwave leadership team.

    Meet Our Leadership

  • Careers at Shockwave

    Ready to help us disrupt the status quo and improve the lives of patients across the globe? 

    Spark Your Career